Ovid Therapeutics Inc. (OVID) stock
OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)
Close on Nov 17, 2026Market cap $433.56MP/E –Yield –
Ovid Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Ovid Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $33.60M, up 24.9% year over year. For fiscal 2025 it was $25.58M, down 30.4% from the year before. Over ten years it grew 14.5% a year on average. The highest annual figure on record is $63.42M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.58M | -30.4% |
| FY2024 | Dec 31, 2024 | $36.77M | +28.6% |
| FY2023 | Dec 31, 2023 | $28.59M | +16.1% |
| FY2022 | Dec 31, 2022 | $24.62M | -47.6% |
| FY2021 | Dec 31, 2021 | $46.94M | -26.0% |
| FY2020 | Dec 31, 2020 | $63.42M | +50.4% |
| FY2019 | Dec 31, 2019 | $42.16M | +24.8% |
| FY2018 | Dec 31, 2018 | $33.79M | -32.4% |
| FY2017 | Dec 31, 2017 | $49.97M | +421.3% |
| FY2016 | Dec 31, 2016 | $9.59M | +45.0% |
| FY2015 | Dec 31, 2015 | $6.61M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.96M | +54.0% |
| Q1 FY2026 | Mar 31, 2026 | $11.18M | +67.9% |
| Q4 FY2025 | Dec 31, 2025 | $6.59M | +11.2% |
| Q3 FY2025 | Sep 30, 2025 | $5.87M | -25.3% |
| Q2 FY2025 | Jun 30, 2025 | $6.47M | -48.6% |
| Q1 FY2025 | Mar 31, 2025 | $6.66M | -36.0% |
| Q4 FY2024 | Dec 31, 2024 | $5.92M | -44.3% |
| Q3 FY2024 | Sep 30, 2024 | $7.86M | +47.3% |
| Q2 FY2024 | Jun 30, 2024 | $12.58M | +109.7% |
| Q1 FY2024 | Mar 31, 2024 | $10.40M | +57.2% |
| Q4 FY2023 | Dec 31, 2023 | $10.64M | +91.5% |
| Q3 FY2023 | Sep 30, 2023 | $5.33M | +2.9% |
| Q2 FY2023 | Jun 30, 2023 | $6.00M | -0.8% |
| Q1 FY2023 | Mar 31, 2023 | $6.62M | -15.5% |
| Q4 FY2022 | Dec 31, 2022 | $5.56M | -69.3% |
| Q3 FY2022 | Sep 30, 2022 | $5.18M | +5.4% |
| Q2 FY2022 | Jun 30, 2022 | $6.05M | -21.3% |
| Q1 FY2022 | Mar 31, 2022 | $7.83M | -51.8% |
| Q4 FY2021 | Dec 31, 2021 | $18.09M | +7.1% |
| Q3 FY2021 | Sep 30, 2021 | $4.92M | -69.0% |
| Q2 FY2021 | Jun 30, 2021 | $7.68M | -52.1% |
| Q1 FY2021 | Mar 31, 2021 | $16.25M | +11.1% |
| Q4 FY2020 | Dec 31, 2020 | $16.88M | +39.5% |
| Q3 FY2020 | Sep 30, 2020 | $15.88M | +36.9% |
| Q2 FY2020 | Jun 30, 2020 | $16.03M | +75.8% |
| Q1 FY2020 | Mar 31, 2020 | $14.63M | +56.6% |
| Q4 FY2019 | Dec 31, 2019 | $12.11M | +40.4% |
| Q3 FY2019 | Sep 30, 2019 | $11.60M | +35.7% |
| Q2 FY2019 | Jun 30, 2019 | $9.12M | +12.3% |
| Q1 FY2019 | Mar 31, 2019 | $9.34M | +10.2% |
| Q4 FY2018 | Dec 31, 2018 | $8.62M | +28.4% |
| Q3 FY2018 | Sep 30, 2018 | $8.54M | +44.8% |
| Q2 FY2018 | Jun 30, 2018 | $8.12M | +33.6% |
| Q1 FY2018 | Mar 31, 2018 | $8.47M | -72.9% |
| Q4 FY2017 | Dec 31, 2017 | $6.71M | +68.2% |
| Q3 FY2017 | Sep 30, 2017 | $5.90M | +118.6% |
| Q2 FY2017 | Jun 30, 2017 | $6.07M | – |
| Q1 FY2017 | Mar 31, 2017 | $31.28M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.99M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.70M | – |
See a number that looks wrong?